No increased risk of pancreatitis seen….
A recent study evaluating the cardiovascular safety and efficacy of saxagliptin has concluded the drug lowers HbA1c and improves microvascular disease. Additionally, saxagliptin showed no increased risk of pancreatitis as some other antihyperglycemic drugs.
The data from the SAVOR TIMI 53 trial, which involved nearly 16,500 patients who were randomly assigned to saxagliptin 5 mg per day or placebo, was presented at the European Association for the Study of Diabetes (EASD) 2013. The primary endpoint was a composite of cardiovascular death, myocardial infarction or ischemic stroke and occurred in 613 patients (7.3%) and 609 (7.2%) patients in the saxagliptin and placebo groups, respectively. Furthermore, mean HbA1c was lower in the saxagliptin group (7.6%) than placebo (7.9%), and 11% of patients treated with saxagliptin saw improvement from microalbuminuria to normoalbuminuria versus 9% in the placebo group.
Overall, saxagliptin was shown to be safe and effective and improve glycemic control by lowering HbA1c and improving microalbuminuria disease; however, physicians should keep in mind that other methods are still necessary to reduce the risk of cardiovascular complications in those patients with diabetes.
- SAVOR TIMI 53 trial shows saxagliptin to be safe and effective
- Saxagliptin lowers HbA1c and improves microalbuminuria disease
- No increased risk of pancreatitis seen with saxagliptin
European Association for the Study of Diabetes Annual Meeting, September 2013, Abstract #34